SCHEMBL6844626

SCHEMBL6844626

CN1CC(=O)N(C)c2cnc(Cl)nc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK4 Q13043 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.39
ABL1 P00519 2/20 0.35
BCR P11274 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
PRKDC P78527 3/20 0.34
RPS6KA3 P51812 2/20 0.34
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PIK3CG P48736 1/20 0.32
PIN1 Q13526 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
MAPT P10636 1/20 0.31
TYRO3 Q06418 1/20 0.30
DYRK1B Q9Y463 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542184 0.84 SMN1; SMN2 (0.40) STK4SMN1; SMN2ABL1BCRCYP11B1
SCHEMBL25462583 0.83 STK4 (0.51) STK4ALDH1A1TSHRPRKDCRPS6KA3
SCHEMBL2874984 0.82 RPS6KA3 (0.36) STK4SMN1; SMN2ABL1BCRPRKDC
SCHEMBL2875624 0.81 PRKDC (0.47) STK4SMN1; SMN2PRKDCPIK3CDPIK3CA
SCHEMBL13814859 0.81 SMN1; SMN2 (0.39) STK4SMN1; SMN2ABL1BCRMAPT
SCHEMBL25463701 0.81 STK4 (0.52) STK4ALDH1A1TSHRPRKDCRPS6KA3
SCHEMBL6844375 0.79 PRKDC (0.45) STK4SMN1; SMN2ABL1BCRPRKDC
SCHEMBL6840359 0.79 PRKDC (0.45) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL11916076 0.78 STK4 (0.47) STK4ALDH1A1TSHRPRKDCRPS6KA3
SCHEMBL7747078 0.78 RPS6KA3 (0.36) STK4SMN1; SMN2ALDH1A1RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572364-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-02-07 US disclosed
WO-2011079118-A1 PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE ELAN PHARMACEUTICALS, INC (US) 2011-06-30 WO disclosed
US-7759347-B2 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-20 US disclosed
US-7759347-B2 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-20 US disclosed
US-20090124628-A1 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 US disclosed
US-20090124628-A1 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572364-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP STK4 1716/4885SMN1; SMN2 1711/4885ABL1 1694/4885
US-20090124628-A1 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments QDPR, DHPS, CYP51A1 STK4 2738/4885SMN1; SMN2 4805/4885ABL1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.